European journal of cancer (Oxford, England : 1990)AdultAgedFemaleHumansMiddle Aged
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial.
Frédérique Penault-Llorca, Amelie Lusque, Thomas Filleron, Kevin Tran, Lili Du, Rick Baehner, Florence Dalenc, Magali Lacroix-Triki, Thomas Bachelot, Fabrice Andre, Pascal Boucher, Jérôme Lemonnier, W Fraser Symmans
Published: 202610.1016/j.ejca.2025.116152
Abstract
AIM: To independently confirm whether the combination of sensitivity to endocrine therapy (SET2,3) index and Recurrence Score® (RS) improves prognostic assessment for patients with hormone receptor-positive (HR+) lymph node-positive (LN+) breast canc…
Preview only. Read the full abstract at the source